A post hoc analysis on the effects of a probiotic mixture on asthma exacerbation frequency in schoolchildren

TABLE 1

Demographic and clinical data in schoolchildren with asthma, taking (active treatment) or not taking (placebo) a probiotic mixture

Demographic characteristics	Total	Placebo	Active treatment
Subjects, n	262	139	123
Age, years	8.7±2.96	8.4±2.72	9.0±3.18
Sex
Female	114 (43.5)	60 (43.2)	54 (43.9)
Male	148 (56.5)	79 (56.8)	69 (56.1)
Asthma severity
Intermittent	203 (77.5)	108 (77.7)	95 (77.2)
Mild persistent	37 (14.1)	21 (15.1)	16 (13.0)
Moderate persistent	22 (8.4)	10 (7.2)	12 (9.8)
Sensitised children
No	116 (44.3)	66 (47.5)	50 (40.7)
Yes	146 (55.7)	73 (52.5)	73 (59.3)
Patients with asthma exacerbations	Placebo	Active treatment	OR (95% CI); p-value
No exacerbation	107 (77.0)	115 (93.5)	4.30 (1.90–9.74); <0.001
At least one exacerbation	32 (23.0)	8 (6.5)
Less than two exacerbations	127 (91.4)	122 (99.2)	11.53 (1.48–90.00); 0.020
Two exacerbations	12 (8.6)	1 (0.8)
Total number of asthma exacerbations	44	9
Clinical judgement
Mild exacerbation	16 (36.4)	0 (0.0)
Moderate exacerbation	26 (59.1)	9 (100.0)
Severe exacerbation	2 (4.5)	0 (0.0)
Duration, days	4.0 (0.0–12.0)	4.0 (0.0–8.0)

Data are presented as mean±sd, n (%) or median (interquartile range), unless otherwise stated.

Vol 8 Issue 2 Table of Contents

Main menu